BioMotiv

13 articles about BioMotiv

• BioMotiv and Bristol-Myers Squibb Announce the Launch of Anteros Pharmaceuticals

  2/4/2020

  BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE: BMY) today announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

• 

  BioMotiv and Bristol-Myers Squibb Launch Anteros Pharma

  2/4/2020

  “Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.

• BioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic Development

  1/13/2020

  Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research

• 

  What Makes BioMidwest a Great Place to Live?

  9/10/2019

  The Midwestern region of the United States is often referred to as “flyover country” by residents of both coasts as a way to diminish or dismiss the importance of the states that make up this part of the nation. But the Midwest can be a great place to live and raise a family.

• BioMotiv and Bristol-Myers Squibb Form Strategic Partnership

  9/4/2019

  Upon the identification of a preclinical candidate molecule, Bristol-Myers Squibb will have the option to acquire the company from BioMotiv under pre-agreed terms.

• 

  Invest with an Option to Buy: Bristol-Myers Squibb Partners with Accelerator BioMotiv

  9/4/2019

  Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate.

• TamRx Launches to Develop Pipeline of Immuno-oncology Products for Treatment of Cancers

  2/7/2019

  New company’s bifunctional technology blocks tumor growth and stimulates the immune system to fight cancer

• BioMotiv And Biogen Expand Strategic Partnership Into Ophthalmology

  9/6/2016

• Charles River And BioMotiv Enter Into Strategic Partnership

  4/14/2016

• BioMotiv And Biogen Form Strategic Partnership In Neuroscience

  9/22/2015

• BioMotiv Attracts $25 Million Investment From Takeda Pharmaceutical Co. Ltd.

  9/26/2014

• Startup Drug-Discovery Company BioMotiv Attracts New Millions and a Key Partner

  8/13/2013

• BioMotiv Secures $46 Million in Funding

  8/5/2013